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1. Introduction
Finding an appropriate definition or a clear classification for biologically occurring pharma‐
ceutical products is a complicated task because of overlapping borders and consequent mis‐
conceptions in this area. Indeed, numerous definitions and classifications for this category of
products have been proposed so far, and different points of view for this concept can be
found in research literature, business, industry, and even the general public [1, 2].
To obtain a better view of biopharmaceutical concept, first, it is necessary to know the
present definitions for the main constituents of the word, that is, pharmaceutical product
and biological product.
According to the WHO, a finished pharmaceutical product (FPP) is “A finished dosage form
of a pharmaceutical product, which has undergone all stages of manufacture, including
packaging in its final container and labeling." [3]
An active pharmaceutical ingredient can be defined as “A substance used in a finished phar‐
maceutical product (FPP), intended to furnish pharmacological activity or to otherwise have
direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to have
direct effect in restoring, correcting or modifying physiological functions in human beings."
[3] Hence, in brief, it can be said that any material, regardless of its origin or structure, with
treatment, diagnosis, or prevention applications and passing regulatory requirements, is a
pharmaceutical product.
On the other hand, the FDA definition for biological products is as follows: “Biological
products or biologics are medical products made from a variety of natural sources (human,
animal or microorganism). Like drugs, some biologics are intended to treat diseases and
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medical conditions or to prevent or diagnose diseases.” [4] Consequently, any product of bi‐
ological origin with treatment, diagnosis, or prevention applications is a biological product.
A biotechnology-derived product is another concept that should be taken into consideration.
It is defined by Walsh as “any pharmaceutical product used for a therapeutic or in vivo di‐
agnostic purpose, which is produced in full or in part by either traditional or modern bio‐
technological means.” [5]
On comparing the definitions for a biotechnology-derived product and a biological product,
both of which should be of biological origin, it is obvious that the key element in the former
definition is the application of biotechnological means for production.
In practice, the regulatory requirements needed for a biotechnology-derived product and a
biological product are methodologically different from the pharmaceutical product due to
their biological essence. For example, the determination of adventitious agents such as vi‐
ruses, transmitting spongiform encephalopathy (TSE), and mycoplasma are included in
most of the related guidelines and pharmacopeias for a biotechnology-derived product and
a biological product.
Finally, a biopharmaceutical is defined by Walsh as “A protein or nucleic acid based phar‐
maceutical substance used for therapeutic or in vivo diagnostic purposes, which is produced
by means other than direct extraction from a native (non-engineered) biological source.”
This definition that will be used in the present chapter for biopharmaceuticals includes all
pharmaceutical products produced by modern biotechnology techniques as well as nucleic
acid (DNA or RNA) based pharmaceutical products for gene therapy. Hence, the overlap‐
ping area between biotechnology-derived products and biopharmaceuticals is the applica‐
tion of modern biotechnological means in their production. However, the differentiating
area can be the application of traditional biotechnological means for the production of bio‐
technology-derived products. In addition, nucleic acid-based pharmaceutical products that
are categorized as biopharmaceuticals are not biotechnology-derived products [6]. Figure 1
illustrates these overlapping and differentiating areas. Moreover, some examples of prod‐
ucts in these categories are shown in Table1.
Biotechnology-derived product by:
Biological products Traditional technology Modern technology Biopharmaceuticals
Blood and blood products Therapeutic proteins fromnatural sources Recombinant proteins Recombinant proteins
Human cells and tissues Antibiotics fully or partiallyfrom microorganisms
Monoclonal antibody
produced by hybridoma
technology
Nucleic acid-based
pharmaceutical products for
gene therapy
Table 1. Some examples of products related to biological, biotechnology-derived, and biopharmaceutical products.
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Figure 1. The schematic representation for biotechnology-derived products and biopharmaceutical categories and
the overlapping areas between them.
2. Methods for biopharmaceutical production
2.1. Production of an original recombinant system
2.1.1. Recombinant DNA technology
The main category of biopharmaceuticals is manufactured via recombinant DNA technolo‐
gy. Indeed, recombinant DNA technologies are enabling techniques that manipulate and en‐
gineer different gene fragments and which have been introduced less than 50 years ago by
the revolutionary invention of Polymerase Chain Reaction (PCR) by Kary Mullis [7].
DNA and RNA extraction from different cell types, cutting DNA fragments using restriction
endonucleases, joining DNA fragments by DNA ligases, PCR to amplify gene fragments,
cloning of the gene fragments into different vectors, introduction of recombinant constructs
into proper hosts, protein expression, extraction, and purification are some of the most
widely used means in recombinant protein production.
Figure 2 schematically represents the summarized process of production of a recombinant
protein. As can be seen from the chart, first, the gene of interest should be isolated and am‐
plified from the original cell. According to the type of the cell, it can be done through direct
total DNA extraction followed by a PCR using proper primers to obtain the gene in prokar‐
yotes. On the other hand, in eukaryotes, due to the existence of introns and some modifica‐
tions that occur in the transcribed mRNA, the process is considerably complicated. Introns
are non-coding sequences which are removed after transcription versus coding sequences
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that are called exons. In addition, mRNA is more modified by the addition of a methylated
guanine (CAP) on its 5’end and a poly-adenine tail on its 3’end. After these modifications,
mature mRNA is exported to the cytoplasm in order to start the translation process. Conse‐
quently, to obtain a gene of interest in eukaryotes, the mature mRNA should be extracted
from the cell, and the complementary DNA should be synthesized followed by amplifica‐
tion of the gene by PCR using proper primers. However, in both cases (prokaryotes and eu‐
karyotes), the short genes can be obtained by a solid-phase synthesis process.
Figure 2. Schematic representation of recombinant protein production process
Based on their sizes, the obtained genes can now be introduced into a proper vector for
maintenance, replication, or expression purposes. Plasmids, cosmids, and bacteriophages
are the most important cloning vectors that are classified according to the size of the DNA
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fragment that can be inserted into them. Ultimately, the new recombinant construct should
be introduced into an expression system for production. Different classes of expression sys‐
tems with their certain merits and disadvantages are available and range from cell systems
such as bacterial, animal, fungal, and yeast cells to transgenic systems such as transgenic
plants and animals [7, 8].
2.1.2. Monoclonal antibody production
2.1.2.1. Classical hybridoma technology
Each specific antibody is secreted by a specific B cell and could recognize a specific region
on the antigen that is called epitope. Each antibody-secreting B cell could be used as a source
of an antibody of interest if it is isolated and cultured in vitro. Nevertheless, B cells are not
considered a satisfactory source, as they are not immortalized and cannot survive for a long
time. The main approach for overcoming this problem is cell hybridization, which includes
the fusion of antibody-secreting B cells with tumor cells (such as mouse myeloma cells) pro‐
liferating ever more. The classical hybridoma technology was first introduced by Georges
Kohler and Cesar Milstein in the mid 1970s for the generation of immortalized hybridoma
cells that could grow in cell culture for a long time and produce the desired monoclonal an‐
tibodies [9, 10]. The basic process (Figure 3) includes the immunization of a mouse with the
desired antigen. The mouse was then sacrificed, and B lymphocytes secreting antibodies
that were selective for the specific epitope on the antigen were isolated from the spleen. The
spleen is considered the most ready source for antigen-specific lymphocytes that provides
access to a large number of antibody-secreting cells [1]. The isolated B cells were subse‐
quently fused with immortal mouse myeloma cells. The resultant hybridoma cells were then
separated from the unfused cells by culturing in specific cell culture media. The cell culture
media for the hybridoma growth and production of monoclonal antibodies have been re‐
viewed in detail by Bols et al. [11].
In general, for the successful fusion of hybridomas, the cells are grown in HAT selection medi‐
um. The selection medium is called HAT, as it has Hypoxanthine, Aminopterin, and Thymi‐
dine.  This  is  because  a  mutation  in  either  the  hypoxanthine-guanine
phosphoribosyltransferase (HGPRT) or the thymidine kinase (TK) gene of the cells would
cause their death in the HAT medium. Generally, a TK-deficient cell (TK-negative mutant) is
resistant to bromodeoxyuridine (BrdU), and an HGPRT-deficient cell (HGPRT-negative mu‐
tant) is resistant to 6-thioguanine (6-TG) and 8-azaguanine. Hence, in order to make myeloma
cells sensitive to HAT (unable to grow in HAT media), they are treated with one of these drugs
before their passage to HAT media.
Normal cells can synthesize the required nucleotides in two pathways: (1) the main one or
de novo biosynthetic pathway, and (2) the alternative one or the salvage pathway (when the
main pathway is blocked).
Aminopterin (a folic acid analog that inhibits dihydrofolate reductase) blocks the activation
of tetrahydrofolate, which is required for the synthesis of nucleotides via the de novo syn‐
thetic pathway, and, therefore, the main pathway is blocked. Thus, in aminopterin-treated
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cells (HGPRT+ and TK+), the synthesis of nucleotides shifts to the salvage pathway only if
hypoxanthine and thymidine are supplied in the medium. HGPRT and TK, the two en‐
zymes, are required for the salvage pathway, and they catalyze the synthesis of purine and
thymidylate from hypoxanthine and thymidine substrates, respectively.
Since unfused myeloma cells lack HGPRT or TK, they cannot use the salvage pathway.
Thus, the unfused myeloma cells get killed in the HAT medium, as both biosynthetic path‐
ways are blocked. Normal unfused B cells die in the HAT medium, as they are not immor‐
talized and cannot grow for a long time. Nevertheless, the fusion of normal B cells with the
HGPRT-or TK-myeloma cells allows the hybridoma cells to grow in HAT medium, as the B
cells provide the necessary enzymes for growth of the hybridoma cells.
Hence, the HAT selection medium offers an ideal environment for the isolation of fused
myeloma and B cells (hybridoma cells) from unfused myeloma cells and unfused B cells, as
this medium allows only the hybridoma cells to survive in the culture.
The production of monoclonal antibodies could be accomplished by ascites (ascitic fluid)
production (in vivo) or by cell culture (in vitro) methods. In the in vivo method, hybridoma
cells are injected intraperitoneally into mice. The peritoneum serves as a growth chamber for
the injected cells. These cells could secrete a high-titered solution of desired antibodies as
they grow in the cavity. Finally, the produced antibodies are extracted from the ascitic fluid
accumulated in the peritoneal cavity [6]. The antibody concentrations typically range be‐
tween 1 and 15 mg/ml. The in vivo method offers a very high concentration of monoclonal
antibody that often does not need more concentration procedures. Nevertheless, monoclonal
antibodies produced by this technique may be contaminated by considerable levels of
mouse proteins and other contaminants that might require more complicated, subsequent
downstream purifications. The other disadvantage of the ascites production is related to ani‐
mal welfare issues, as these could cause distress in mice.
Currently, more than 90% of monoclonal antibodies are produced by in vitro techniques [12]
that use large-scale manufacturing plants containing several 10,000-L or larger culture bio‐
reactors [13]. The in vitro method of monoclonal antibody production decreases the use of
mice and also avoids the need for experienced personnel for animal handling. Regardless of
the privileges and importance of the in vitro methods of antibody production, there are
some situations in which this method is not applicable; for instance:
1. Hybridoma cells do not adapt well to in vitro conditions.
2. Downstream purification methods cause protein denaturation or decreased antibody
activity.
3. The cell line cannot maintain the production of monoclonal antibodies.
4. When hybridoma cells are contaminated with infectious agents (such as yeasts or fun‐
gi), the cells must often be passed through mice. Since removal of the organisms cannot
be accomplished by current antimicrobial drugs, thus the in vivo method may save a
valuable hybridoma.
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5. When in vitro methods result in monoclonal antibodies that are glycosylated at posi‐
tions different from those harvested from mouse ascites, they affect antigen-binding ca‐
pacity as well as biological functions [12].
Taken together, the cell culture technique is a method of choice for large-scale monoclonal
antibody production due to the simplicity of the cell culture and financial considerations
without ethical concerns that are related to animal use.
Figure 3. The diagram of the monoclonal antibody production via classical hybridoma technology
2.1.2.2. Chimeric and humanized antibodies
In 1986, about 10 years after the conception of monoclonal antibody technology, Orthoclone
OKT3 was approved by the FDA for use in patients with acute rejection of a transplanted
kidney [14]. Unfortunately, early clinical applications of murine monoclonal antibodies were
disappointing. This was due to the fact that monoclonal antibodies produced via the classi‐
cal method are of murine origin and are, therefore, immunogenic to human subjects. In gen‐
eral, patients receiving an antibody exhibit HAMA responses (human anti-mouse
antibodies) within two weeks. Multiple infusions of murine monoclonal antibodies signifi‐
cantly enhance the HAMA reactions [6]. In addition, the immune system eliminates the
murine monoclonal antibody molecule. Thus, murine monoclonal antibodies demonstrate
short serum half lives after administration to humans. Furthermore, the other main difficul‐
ty related to murine monoclonal antibodies is the poor recognition of the Fc region by hu‐
man effector systems of complement and Fc receptors.
Thus, new strategies that are used for producing humanized mouse antibodies that are less
immunogenic have been discovered. The first strategy includes the production of functional
specific recombinant IgG molecules consisting of mouse variable regions and human con‐
stant regions; these are known as chimeric antibodies. Taken together, in the chimeric anti‐
body, 8 out of 12 domains are of human origin (constant regions of the heavy and light
chains) (CH and CL) [15]. Chimeric antibodies exhibit reduced HAMA responses compared
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with mouse antibodies, but the affinity and the selectivity are the same. Furthermore, since
the Fc region contains human sequences, the activation of Fc-mediated immune effector
functions is allowed.
To further minimize the antigenicity of murine antibodies, humanized antibodies were devel‐
oped. For their generation, hyper-variable complementarity-determining regions (CDRs) of the
specific murine antibody are transferred to a fully human framework. In comparison with the
mouse antibodies, humanized antibodies suggest a lower occurrence of HAMA responses.
Further efforts have been invested in the development of technologies that generate fully hu‐
man monoclonal antibodies. One of the approaches entails the development of transgenic mice,
in which a repertoire of human immunoglobulin germline gene segments is inserted into the
mouse genome. After the immunization of these mice, they produce fully human antibodies,
which can subsequently be separated with the classical hybridoma technology [15].
Figure 4 illustrates the schematic structures of mouse, chimeric,  humanized, and human
antibodies.
Figure 4. The structure of mouse (shown in red color), chimeric, humanized (shown in black color), and human anti‐
bodies. Chimeric antibodies comprise mouse variable regions and human constant regions. Humanized antibodies
consist of murine hyper-variable complementarity-determining regions (CDRs) that are grafted to fully human frame‐
work.
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2.2. Mass production of a recombinant product
Mass production of recombinant products can be achieved in a process that is divided into
two main sections called upstream and downstream processing, as schematically depicted in
Figure 5.
Figure 5. Mass production of a recombinant product.
The first step, the upstream processing step, is the mass production of a recombinant protein
via the fermentation process. The original recombinant system that is used for the expres‐
sion of the recombinant protein (i.e. in the form of a recombinant plasmid maintained in a
suitable host cell) forms the cell deposit in a cell banking system. There are two levels of cell
deposits in the cell banking system: The first line is called master cell bank, which is prepared
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directly from a culture of the original recombinant system that includes several hundred
stored ampoules.
The second line that is referred to as the working cell bank is produced from a single master
cell bank ampoule. Each ampoule from the working cell bank is thawed and used to seed
the fermentor for the production of a batch. Obviously, the fermentation process for various
recombinant systems, such as bacterial fermenting systems or animal cell systems, is quite
different and needs its own certain requirements.
On the other hand, downstream processing, which is the next step, refers to the purification of
the mass produced protein. The first step in downstream processing is the initial extraction
and concentration of the product, which depends on the situation of the expressed protein;
that is, it should be extracted from the pellet cells for intracellular proteins or from the su‐
pernatant for extracellular proteins after centrifugation.
The second stage entails (1) several chromatographic steps that complete the purification of
the product; (2) the potency test; (3) the addition of suitable excipients; (4) sterilization; (5)
filling of the product in its final form (liquid or solid) into the final container before sealing;
and labeling [6].
3. Sources of biological contamination of biopharmaceuticals
In line with conventional pharmaceutical products, the main sources of biological contami‐
nation in biopharmaceuticals can be related to raw materials and the production environ‐
ment. Indeed, the biological contaminant content of any pharmaceutical product is a
representative of their starting materials and the production environment flora.
3.1. Raw materials
Animal origin materials, such as cell culture media, sera, and supplements that are exten‐
sively used in biopharmaceutical production, are of high contamination risk. These materi‐
als can be considered the main source for the contamination of biopharmaceuticals with
adventitious agents such as TSEs, viruses, and mycoplasmas. Therefore, they should be sup‐
plied from reliable resources, and special attention should be paid to their quality control
procedure. It should be ensured that all raw materials, especially those of high risk, gain
quality specifications for current good manufacturing practice.
Standard methods for sterilization of cell culture media, sera, and supplements should be
established according to the properties of the materials. Due to the heat-labile nature of the
majority of materials used in biopharmaceutical production, autoclaving is usually replaced
with alternative strategies such as filter-sterilization or less frequently high-temperature,
short-time treatment strategies. In spite of the routine filter-sterilization procedure that uses
0.22 μm, it is usually performed with 0.1-μm membrane filters due to the risk of contamina‐
tion with adventitious agents.
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Furthermore, high-temperature, short-time treatment strategies are sometimes employed for
the elimination of biological contaminants from small solutes such as vitamins and amino
acids [16].
Another important raw material that is used in the production of any pharmaceutical prod‐
uct, including biopharmaceuticals, is water, which can be considered an important source
for contamination, with water-borne bacteria such as Pseudomonas spp., Alcaligenes spp.,
Flavobacterium spp., Chromobacter spp., and Serratia spp. Water for pharmaceutical pur‐
poses is discussed in detail in the USP [17]. Due to the fact that the intended administration
of biopharmaceuticals in the majority of cases is via injection, Water for Injection (WFI)
which is sterile and apyrogen is routinely used in this area.
3.2. Production environment
Pharmaceutical products’ contamination may occur from the transformation of microorgan‐
isms from the production environment to the product. The production environment in‐
cludes air, surfaces, instruments, equipments, and personnel.
The main groups of microorganisms that are isolated from air are the spore-forming bacteria
(Bacillus spp. and Clostridium spp., the non-sporing bacteria Staphylococcus spp., Streptococ‐
cus spp., and Corynebacterium spp.), the molds (Penicillium spp., Cladosporium spp., Asper‐
gillus spp., and Mucor spp.), and the yeast (Rhodotorula spp.). These contaminants may be air
borne or can be initiated from process equipment or personnel [16]. Consequently, environ‐
mental monitoring programs in a production environment are essential actions. Furthermore,
the critical operations in biopharmaceutical production should be performed in controlled en‐
vironments or clean rooms. A clean room is a place with high control of the entrance of parti‐
cles via the establishment of some air filters called high-efficiency particulate air (HEPA) filters.
HEPA filters made from a microglass material with a pleated construction system provide a
large surface area that efficiently filters the incoming air and generates a constant air motion.
Based on the permitted quantity of viable microorganisms and particulates, various classes of
clean rooms can be established using HEPA filters with required efficiencies.
According to the EC Guide to Good Manufacturing Practice for Medicinal Products (EC GGMP),
four grades for clean rooms are available, such as grade A, B, C, or D, based on the number
of viable microorganisms and particulates (Table 2).
Clean room grade Maximum permitted number ofparticles/m 3
Maximum permitted CFU of viable
microorganisms/m 3 in air sample
A 3500 <1
B 3500 10
C 350000 100
D 3500000 200
Table 2. Clean room grades according to the number of viable microorganisms and the number of particulates
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Critical operations such as inoculum preparation and aseptic filling are generally performed
in the highest air grade (A); however, less critical operations can be performed in lower
grades or even non-classified air.
In addition to the establishment of suitable filters in the clean rooms, special attention
should be paid to the position, type, and texture of surfaces, floors, and fixtures. They
should be made from smooth and chemically stable materials. In addition, a distinct transfer
lock area should exist before entry to the clean room for sanitization of materials and per‐
sonnel or garment changing. Furthermore, all doors should be interlocking [6].
4. Hazards of biological contamination of biopharmaceuticals
Similar to other pharmaceuticals, biological contamination of biopharmaceuticals may per‐
haps cause product spoilage. It may result in product metabolization by microorganisms,
and, therefore, lead to a decrease in biopharmaceutical potency. The product spoilage may
also provide a potential health hazard to patients and lead to outbreaks of infections that
may cause additional complications. In addition, microbial-derived agents secreted in prod‐
ucts such as endotoxins can be hazardous to a patient's health.
5. Determination of biological contaminants
5.1. Bacteria and fungi
Bacteria and fungi can be considered important contamination sources for all kinds ofphar‐
maceutical products, including biopharmaceuticals; hence, the control of them is of critical
importance. The control of both bacteria and fungi is considered to be worthy of mandatory
tests for nearly all kinds of pharmaceuticals in pharmacopoeias. All the related tests and
procedures are covered in detail in the major pharmacopoeias such as USP and EP [17, 18].
Since  almost  all  the  biopharmaceuticals  are  administered intravenously,  general  sterility
testing must be carried out for these products. Basically, sterility testing can be defined as
"a test that evaluates whether a sterilized pharmaceutical product is free of contaminating
microorganisms."  The  European  Pharmacopoeia  (2002)  proposes  two  media  for  sterility
testing:
(1) fluid mercaptoacetate medium (also known as fluid thioglycollate medium), which is main‐
ly appropriate for the culture of anaerobic organisms at 30–35°C; and (2) soyabean casein di‐
gest medium, which is used for the culture of both aerobic bacteria at 30–35°C and fungi at
20–25°C.
Two main methods are used for sterility tests: (1) direct inoculation of the test samples in the
media mentioned earlier; or (2) filtration of the test material through a sterile membrane fil‐
ter with a pore size of 0.45 μm; then, the filter containing any microorganism present in the
fluids is divided aseptically, and portions are transferred to the media.
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The eradication of bacteria and fungi from the products is generally carried out via inactiva‐
tion and sterile filtration.
5.2. Endotoxins
Since most of the biopharmaceuticals are administered intravenously, finished-product bio‐
pharmaceuticals must be sterile and free from pyrogenic substances. The endotoxin limit for
the intravenous administration of pharmaceutical and biological products is 5 endotoxin
units (EU)/kg of body weight/hour by all pharmacopoeias [19]. Hence, the detection and re‐
moval of pyrogenic substances, especially endotoxins (lipopolysaccharides in the cell wall of
gram-negative bacteria), are necessary to ensure safety of biopharmaceutical products. Cur‐
rently available methods for endotoxin detection include the U.S. Pharmacopeia rabbit test
and the Limulus amebocyte lysate (LAL) test [7].
The rabbit pyrogen test entails measurements of the rise in body temperature of rabbits after
an intravenous injection of a test substance. The presence of pyrogens of all kinds can be
tested using this method. However, this method suffers from a number of disadvantages
and limitations: (1) Endotoxin tolerance occurs after repeated use of rabbits; (2) variations in
the response depending on sex, age, and species; (3) differences between the responses of
rabbits and humans to various pyrogen types; and (4) the rabbit pyrogen test is inadequate
for sera, radiopharmaceuticals, chemotherapeutics, analgesics, cytokines, immunosuppres‐
sive agents, and others [20].
Accordingly, the use of the rabbit pyrogen test has been reduced. Nowadays, the most wide‐
ly used endotoxin detection systems are based on the highly sensitive LAL test. It is based
on the coagulation cascade of the blood of a horseshoe crab, Limulus polyphemus, which is
induced by lipopolysaccharide. The currently known methods for lipopolysaccharide detec‐
tion entail (1) gel-clot assay, (2) turbidimetric LAL technique, and (3) the chromogenic LAL
technique.
The gel-clot assay is a limit test that provides simple positive or negative results. The LAL
reagent is introduced to a sample, and the test material is considered endotoxin positive if a
gel is formed via a clotting reaction.
The turbidimetric and the chromogenic LAL techniques are quantitative tests. The former is
based on the fact that turbidity increases as a result of the precipitation of the clottable pro‐
tein that is related to endotoxin concentration in the sample. The optical density is read by a
spectrophotometer at either a fixed time (for the end-point method) or progressively (for the
kinetic assay) as turbidity develops.
The  chromogenic  LAL technique  makes  use  of  a  synthetic  substrate  which  contains  an
amino acid sequence similar to that of the clottable protein, coagulogen, in order to detect
endotoxin.  The  enzyme  cleaves  a  yellow-colored  substance  from  the  chromogenic  sub‐
strate,  and  the  color  intensity  produced  is  proportional  to  the  amount  of  endotoxin
present in the sample.
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Endotoxins are temperature and pH stable, and, therefore, their removal is one of the most
challenging issues. Numerous techniques are used to reduce endotoxin contamination of bi‐
opharmaceuticals, including ion-exchange chromatography, sucrose gradient centrifugation,
gel filtration chromatography [19], affinity adsorption [21], charged membrane/depth filtra‐
tion, and ultrafiltration [22].
5.3. Viruses
Owing to the risks of transmission of adventitious agents to patients, the different cell levels
should be studied for the absence of these agents. Among the adventitious agents, special
attention should be paid to viruses that are capable of contaminating the original species.
Generally, the virological safety of biopharmaceuticals includes several levels of control at
various manufacturing stages, including 1 - rigorous screening of cell banks (both master
cell bank and working cell bank) for viruses; 2 - screening of each cell culture harvest for
adventitious agents; and 3 - a demonstration that the purification process can clear potential
adventitious agents [15].
The detection of viruses in cell lines can be carried out via various techniques. The common‐
ly used methods of detecting viral infections include
• co-cultivation assays (specific in vitro tests),
• in vivo assays,
• antibody production in animals (MAPs, RAPs, or HAPs),
• immunoassays for viral specific proteins,
• Transmission Electron Microscopy (TEM),
• Polymerase Chain Reaction (PCR).
For the co-cultivation assays (specific in vitro tests), the cells used for production, or cul‐
ture supernatant, or the final product are incubated with the detector cells.  The detector
cell  lines  are  susceptible  to  different  viruses  and are  used to  detect  desired viruses  via
monitoring subsequent cytopathic effects, hemadsorption, morphological changes, or oth‐
er signs of viral infection. The detector cells usually contain humans, primates, and cells
from the same species.
The in vivo assay can be performed by the inoculation of cells or cell lysates into animals,
including newborn and adult mice, guinea pigs, rabbits, or embryonated chicken eggs to de‐
tect viruses. The animals are consequently monitored for any abnormality.
Species-specific viruses potentially present in rodent cell lines can be examined using assays
for antibody production in the animals. The MAP, RAP, and HAP (mouse, rat, and hamster
antibody production assays, respectively) tests involve an injection of the test article into the
animals. The inoculated animals are bled after four weeks, and the sera are tested for the
presence of the antibodies against the specific viral antigens. For instance, Hantaan virus,
Lactic Dehydrogenase virus, and Sendai virus have been screened using MAP.
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An immunoassay for viral-specific proteins can be undertaken through production of the
relevant antibodies after an injection of a virus of interest into animals. Currently commer‐
cially available immunoassays are able to detect various viruses.
Another method that is used for virus detection is TEM (Transmission Electron Microscopy).
TEM is a quantitative assay that is based on the visualization and morphological identifica‐
tion of virus particles in samples [23].
Nevertheless, more sensitive methods, such as the PCR identification methods, can be em‐
ployed for the detection of sequences of the viruses [16].
Since the biopharmaceuticals can be originated from mammalian cell lines with a high risk
of endogenous retroviruses, on one hand, and these products may be infected with adventi‐
tious viruses through processing, on the other hand, virus inactivation and removal steps in
the purification process are required [24]. These entail gamma irradiation, low pH treat‐
ment, or virus filtration.
Indeed, ensuring the absence of virus contamination in biopharmaceuticals is challenging.
For instance, a limited number of commercial poultry vaccines were contaminated by avian
leukosis virus even after routine quality assurance procedures. In addition, reovirus was
found as a contaminant in urokinase. On the whole, sourcing and testing alone cannot guar‐
antee the virological safety of biopharmaceuticals owing to some limitations: the limit of
sensitivity for cell culture and PCR tests and also due to the fact that cell culture or in vivo
tests are not able to detect all known kinds of potential contaminants [25]. Thus, practical
methods are required for the virological safety of biopharmaceuticals, which involve the in‐
clusion of risk assessment as well as management policies.
5.4. Mycoplasma
Mycoplasmas are the smallest free-living and self-replicating organisms in nature that are
sized between 50 and 500nm. They lack a rigid cell wall and, consequently, are highly pleo‐
morphic from round to filamentous. They are filterable and penicillin-resistant forms. Fur‐
thermore, their membrane contains sterol and due to this, mycoplasmas require the addition
of serum or cholesterol to the growth medium. They grow on special media in aerobic or
anaerobic conditions with optimum growth at 37°C and pH 7.0 and form with a “fried egg”
morphology on agar media (Figure 6).
Mycoplasma contamination of cell culture systems for the production of mycoplasmas is a
critical problem due to its effect on various parameters within the cell culture system. Myco‐
plasma contaminates cell cultures approximately without any sign, and it persists for a long
time. Indeed, mycoplasma-positive cell cultures can be considered the major source of bio‐
pharmaceutical infection, and they should be discarded or effectively decontaminated. Tak‐
en together, mycoplasma-positive cell cultures pose a serious problem and should be
effectively detected and eradicated [26].
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Figure 6. Mycoplasma colonies with fried egg morphology on mycoplasma agar medium. Picture was taken at Myco‐
plasma Reference laboratory, Razi vaccine and serum research institute, Iran
Different methods are used in international pharmacopoeias and guidance for detecting my‐
coplasma in biological test samples, mainly categorizing them as direct assay by microbio‐
logical culture, indirect assay by indicator mammalian cell culture, and PCR.
Direct assay by microbiological culture: The principle of detection is based on the growth of
mycoplasma on supporting agar and liquid media (broth). First, the test sample is intro‐
duced into a special broth culture, is incubated for an appropriate time, and, consequently, it
is sub-passaged to plate agar. After the required incubation period, the presence of myco‐
plasma colonies is observed microscopically in the agar plates (Figure 6).
Indirect assay by indicator mammalian cell culture: The indirect method requires the co-cul‐
tivation of the test sample with an indicator cell line for two to three days. Typically, VERO
cells with a large cytoplasm area around the nucleus were used. Consequently, the cells
were stained using a DNA binding stain (such as Hoechst stain) that binds specifically to
DNA and is observed via fluorescent microscopy. Due to the affinity of mycoplasmas for the
mammalian cell membrane, mycoplasmas appear as granules surrounding the nucleus.
Mycoplasma PCR: In this method, detection is carried out using specific oligonucleotide pri‐
mers for the amplification of mycoplasma DNA. This method is specially recommended for
detecting contamination with the non-cultivable strains of M. hyorhinis [27].
On the whole, it is advisable to use two different methods in the detection of mycoplasmas
in order to allow for the differentiation between false-positive and false-negative results.
5.5. DNA
The importance of DNA contamination detection in biopharmaceuticals is related to the fact
that the DNA from some sources such as hybridoma cell lines in monoclonal antibody pro‐
duction may act as active oncogenes. These kinds of DNA contaminants can be introduced
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and expressed in human cells and result in the initiation of cancer cells. According to guide‐
lines, the acceptable level of residual DNA in recombinant products is 10 pg per therapeutic
dose. DNA hybridization studies that use radiolabeled DNA probes with a specific nucleic
acid sequence constitute one of the most widely used methods for the detection of DNA
contaminants in the product to a nanogram (ng) range [6]. The important steps involved in
DNA hybridization are shown in Figure 7.
Figure 7. The main steps of the DNA hybridization procedure
5.6. Cross-contamination
Cell cultures may be infected with other cell types due to the use of contaminated items or
operator mistakes. Also fail of the sterilization process can be another reason. The detection
of cross-contamination is very challenging due to the fact that macroscopic and microscopic
properties of the original and contaminant cells are commonly the same. Cross-contamina‐
tion in the production of biopharmaceuticals would prove to be disastrous and terrible.
Various tests for detecting cross-contaminations can be applied; however, a product-specific
identity test will be the best choice [16].
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6. Summary
Microbial quality control plays a prominent role in the manufacture of safe and effective bio‐
pharmaceuticals. The main sources of microbial contamination can be related to raw materi‐
als and the production environment. The main categories of raw materials that are involved
in the manufacturing of biopharmaceuticals with a high risk of contamination are those of
animal origin such as cell culture media, sera, and supplements. The production environ‐
ment includes air, surfaces, instruments, equipments, and personnel. All these can be con‐
sidered the main source for the contamination of biopharmaceuticals with adventitious
agents such as viruses, bacteria, fungi, transmitting spongiform encephalopathy, and myco‐
plasma. The use of contaminated biopharmaceuticals causes product spoilage, which may
lead to (i) metabolization of the therapeutic agents by microorganisms, thus bringing about
a decrease in the potency of the therapeutic agent; (ii) a potential health hazard to patients
as a result of either infectious diseases or microbial-derived agents such as endotoxins that
are secreted into products.
Various methods are used for detecting and eliminating different biological contaminants
that are used in the manufacturing of biopharmaceuticals. Generally, bacteria and fungi can
be detected by standard sterility testing or macroscopic and microscopic characteristics, as
well as biochemical tests. In addition, viruses can be detected via a number of methods such
as co-cultivation assays (specific in vitro tests), in vivo assays, antibody production in ani‐
mals (MAPs, RAPs, or HAPs), immunoassays for viral specific proteins, TEM, or PCR. The
detection of endotoxin can be carried out using the pharmacopeial rabbit test or LAL test.
The available approaches for the detection of mycoplasma include direct assay using special
culture media, indirect assay by mammalian cells, and DNA staining, as well as PCR. Fur‐
thermore, DNA hybridization is a widely used approach for the detection of DNA contami‐
nants in biopharmaceuticals. The best method for cross-contamination detection includes a
product-specific identity test.
With regard to the collection of tests for biological quality control of biopharmaceuticals
summarized in this chapter, it is obvious that various sets of methods are available in differ‐
ent guidelines and pharmacopeias which are complicated and problematic. The develop‐
ment and compilation of harmonized guidelines for biological quality control of
biopharmaceuticals is a critical necessity that can facilitate the control of the safety of these
ever-increasing products.
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